株式会社JiMED

JiMED operates at the intersection of implantable medical devices, neuroscience, assistive technology, and artificial intelligence. Its differentiation is technical and clinical: the company is developing a wireless implantable BCI that measures high-resolution brain activity and decodes signals with AI so people with severe physical impairments, including ALS patients, can interact with PCs and other devices without physical movement. This focus distinguishes JiMED from broader AI software companies and from non-implantable communication aids. The company also emphasizes end-to-end development, manufacturing, and sales of implantable BMI/BCI devices, although the extent of commercialization is not publicly established. JiMED has attracted capital from university-affiliated and specialist investors, including Keio Innovation Initiative, Kyoto University Innovation Capital, Osaka University Venture Capital, and Mizuho Capital. That investor mix supports its positioning as a research-led, translational medical-device venture. Its principal market constraints remain regulatory validation, surgical implementation, long-term implant safety, signal reliability, reimbursement, and proof of improved patient outcomes.

JiMED’s trajectory shows a progression from university-origin research commercialization toward later-stage financing for wireless implantable BCI development. The company was founded on Mar 26, 2020 and recorded a $1.81 million Seed round on Mar 31, 2021, with Mizuho Capital and Osaka University Venture Capital participating. A further $1.10 million venture round was announced on Feb 28, 2023. Additional financing followed with a $2.29 million Series A announced on Feb 13, 2025, backed by Green Core, Keio Innovation Initiative, and Kyoto University Innovation Capital. On Jun 18, 2026, JiMED raised approximately $2.05 million in another venture round, expanding participation to five identified investors and bringing structured cumulative funding to approximately $7.24 million. Product activity centers on a wireless implantable BCI that measures high-resolution brain waves and uses AI to operate external devices. Consequently, the clearest inflection points are financing continuity and expansion of the investor base, while the next stage of growth depends on clinical translation and device commercialization.